Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2023-09-03 Board/Management Inform…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Paul Woodard, M.D. appointed as Chief Medical Officer 3 pages 135.2KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement regarding the appointment of a new Chief Medical Officer at Imugene Limited. It contains no financial data, no report or presentation, and no mention of voting results, dividends, or regulatory certifications. It is a management change announcement, specifically about senior management appointment. Therefore, it fits the category of Board/Management Information (MANG). The document length is about 5147 characters, which is sufficient for a full announcement rather than a brief note or report publication announcement.
2023-09-03 English
Imugene Appoints Dr John Byon as SVP Clinical Development 3 pages 133.9KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement about the appointment of Dr John Byon as Senior Vice President of Clinical Development at Imugene Limited. It contains no financial data, no report or results, and no mention of any regulatory filings or financial performance. It is a management announcement regarding a change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is about 5,000 characters, and it is a standalone announcement, not a report or a notice of report publication.
2023-08-31 English
Notice of Extraordinary General Meeting/Proxy Form 25 pages 1.3MB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'Imugene Limited 2023 Extraordinary General Meeting' and contains detailed information about the upcoming Extraordinary General Meeting (EGM), including the date, time, location, webcast details, proxy voting instructions, and a list of resolutions to be voted on. The resolutions primarily concern the approval of issuance of shares and options to directors and investors, which is typical content for a meeting notice. There is no financial data, earnings information, or management discussion present. The document is not a report but a notice and invitation to shareholders to attend and vote at the EGM. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings such as EGMs.
2023-08-29 English
Preliminary Final Report 25 pages 2.4MB
Annual Report Classification · 95% confidence The document is titled 'Preliminary Final Report 2023' for the year ended 30 June 2023 and includes detailed financial results such as net loss, net tangible assets, cash reserves, and a review of operations and activities. It also contains extensive operational updates on clinical trials, FDA clearances, collaborations, and patent information. The presence of detailed financial data and comprehensive operational review indicates this is a full annual financial report rather than a brief announcement or presentation. The document also references Appendix 4E, which is typically associated with preliminary final reports in Australian markets, reinforcing that this is a full annual report. The length of the document (15,000 characters) and the inclusion of substantive financial and operational information confirm it is not merely an announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K equivalent).
2023-08-24 English
Application for quotation of securities - IMU 8 pages 30.4KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Application for quotation of +securities' and details the application for quotation of securities on the ASX for Imugene Limited. It includes information about the number and type of securities to be quoted, issue dates, distribution schedules, and issued capital following quotation. The document references previous announcements (Appendix 3B) related to the securities issuance. There is no financial performance data, earnings information, management discussion, or legal proceedings. The document is an official announcement related to the listing or quotation of securities on the exchange, which aligns with capital or financing updates. Therefore, the document fits best under the category 'Capital/Financing Update (CAP)'. The document length is 6461 characters, which is sufficient to contain substantive details about the securities quotation rather than a brief notice. Hence, the classification is CAP with high confidence.
2023-08-24 English
Cleansing Notice 2 pages 212.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 25 August 2023, announcing the issue of approximately 411.2 million fully paid ordinary shares via a placement. It references section 708A(5)(e) of the Corporations Act 2001, which relates to disclosure notices for share issues without a prospectus. The content focuses on the details of the share issuance and compliance with relevant disclosure laws. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory announcement about a capital raising event (placement of shares). Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 3733 characters, which is consistent with a typical announcement rather than a full report.
2023-08-24 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.